Darcie Sandschafer
Overview
Explore the profile of Darcie Sandschafer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stefanski H, Kuxhausen M, Bo-Subait S, Kobusingye H, Mattila D, Schenfeld J, et al.
Blood Adv
. 2024 Apr;
8(15):4196-4206.
PMID: 38687368
Allogeneic hematopoietic cell transplantation is a life-saving procedure used to treat a variety of devastating diseases. It requires hematopoietic stem cells collected via filgrastim-mobilized peripheral blood stem cells (PBSCs) or...
2.
Wyrwicz L, Rodriguez Sanchez C, Sanchez-Rovira P, Lewis S, Sandschafer D, San T
Future Oncol
. 2024 Feb;
20(13):821-832.
PMID: 38305004
Trastuzumab-anns is an intravenously administered biosimilar to trastuzumab approved by the EMA and US FDA for treatment of HER2+ early and metastatic breast cancer as well as metastatic gastric cancer....
3.
Jin R, Ogbomo A, Accortt N, Lal L, Bishi G, Sandschafer D, et al.
Ther Adv Med Oncol
. 2023 Jun;
15:17588359231182386.
PMID: 37360769
Background: Bevacizumab-awwb (MVASI) was the first U.S. Food and Drug Administration-approved biosimilar to Avastin (reference product [RP]) for the treatment of several different types of cancers, including metastatic colorectal cancer...
4.
De Oliveira Brandao C, Lewis S, Sandschafer D, Crawford J
Curr Med Res Opin
. 2023 Mar;
39(5):707-718.
PMID: 36976784
Chemotherapy-induced febrile neutropenia (FN) is a medical emergency that may occur in patients with malignancies receiving myelosuppressive chemotherapy. FN requires early therapeutic intervention since it is associated with increased hospitalizations...
5.
Jin R, Mahtani R, Accortt N, Lawrence T, Sandschafer D, Loaiza-Bonilla A
Ther Adv Med Oncol
. 2022 Jan;
13:17588359211041961.
PMID: 35003333
Background: In July 2019, bevacizumab-awwb and trastuzumab-anns were marketed in the USA as the first therapeutic oncology biosimilars. We aimed to investigate the initial real-world use of bevacizumab-awwb and trastuzumab-anns...
6.
Rhodes W, DeClue R, Accortt N, Jin R, Sandschafer D, Wertz D, et al.
Future Oncol
. 2021 Oct;
17(36):5119-5127.
PMID: 34698523
Evaluated real world use of bevacizumab-awwb (MVASI), a bevacizumab biosimilar, for treating metastatic colorectal cancer (mCRC). Adult mCRC patients who received bevacizumab-awwb during the first year after market availability were...